A new US company has been launched to progress a small molecule drug to inhibit the replication of SARS-CoV-2 and other RNA viruses. CoviCept Therapeutics Inc has received seed funding of $2.3 million from Forbion, the Netherlands-based life sciences venture capital firm. The new company is based in San Diego, US.
